ICU Medical (NASDAQ:ICUI) Issues FY 2025 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 6.550-7.250 for the period, compared to the consensus EPS estimate of 7.130. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Wednesday, December 11th. KeyCorp upped their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.67.

ICU Medical Price Performance

ICU Medical stock opened at $146.33 on Friday. The firm’s 50-day moving average is $160.42 and its two-hundred day moving average is $166.08. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. ICU Medical has a 12-month low of $93.36 and a 12-month high of $196.26. The stock has a market capitalization of $3.58 billion, a P/E ratio of -32.02 and a beta of 0.63.

Insider Buying and Selling

In related news, CEO Vivek Jain sold 1,373 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total value of $213,474.04. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. This trade represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.